Skip to main content
SpringerLink
Log in

Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose

  • Konsensus Bericht
  • Published:
Wiener Klinische Wochenschrift Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, Piantadosi CA (2001) Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164: 1988–1996

    PubMed  CAS  Google Scholar 

  2. Voelkel NF, Cool C, Taraceviene SL, G MW, Yeager M, Bull T, Kasper M, Tuder RM (2002) Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med 30: S251–256

    Article  Google Scholar 

  3. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, Geraci MW (2001) Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314–318

    PubMed  CAS  Google Scholar 

  4. Berger RM, Geiger R, Hess J, Bogers AJ, Mooi WJ (2001) Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease. Am J Respir Crit Care Med 163: 1493–1499

    PubMed  CAS  Google Scholar 

  5. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739

    Article  PubMed  CAS  Google Scholar 

  6. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ (1998) Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 351 (9104): 726–727

    Article  PubMed  CAS  Google Scholar 

  7. Cowan KN, Jones PL, Rabinovitch M (2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105: 21–34

    Article  PubMed  CAS  Google Scholar 

  8. Zaidi SHE, You XM, Ciura SM, Husain M, Rabinovitch M (2002) Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516–521

    Article  PubMed  CAS  Google Scholar 

  9. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M (2000) Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6: 698–702

    Article  PubMed  CAS  Google Scholar 

  10. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA 3rd, Loyd JE (2001) Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345: 319–324

    Article  PubMed  CAS  Google Scholar 

  11. Morse JH, Deng Z, Knowles JA (2001) Genetic aspects of pulmonary arterial hypertension. Ann Med 33: 596–603

    Article  PubMed  CAS  Google Scholar 

  12. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF (2001) Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88: 555–562

    PubMed  CAS  Google Scholar 

  13. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethaite PA (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348: 500–509

    Article  PubMed  CAS  Google Scholar 

  14. Rich S (ed) (1998) Executive summary from the World Symposium on Primary pulmonary Hypertension Evian, France, co-sponsered by the World Health Organisation. (http:/www.who.int/cvd/pph/html)

  15. Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003) Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41: 1028–1035

    Article  PubMed  Google Scholar 

  16. Ziesche R, Petkov V, Wittmann K, Kopatschka J, Stiebellehner L, Schenk P, Germann P, Röder G, Ullrich R, Block LH (2000) Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 83: 406–409

    Article  PubMed  CAS  Google Scholar 

  17. Higenbottam T, Wheeldon D, Wells F, Wallwork J (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet i (8385): 1046–1047

    Article  Google Scholar 

  18. Hantano S, Strasser T (eds) (1975) Primary pulmonary hypertension. Report on the WHO Meeting. World Health Organisation, Geneva. In: Higenbottam TW (ed) Therapy for patients with pulmonary vascular disease. N Engl J Med 306: 557–564

    Google Scholar 

  19. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343–349

    PubMed  Google Scholar 

  20. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580–587

    PubMed  CAS  Google Scholar 

  21. Jones DK, Higenbottam TW, Wallwork J (1987) Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). British Heart Journal 57: 270–278

    Article  PubMed  CAS  Google Scholar 

  22. Higenbottam T (1987) The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am Rev Resp Dis 136: 782–785

    PubMed  CAS  Google Scholar 

  23. Jones K, Higenbottam T, Wallwork J (1989) Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 96: 784–789

    Article  PubMed  CAS  Google Scholar 

  24. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66: 334–338

    PubMed  CAS  Google Scholar 

  25. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacy-clin (epoprostenol). Results of a randomized trial. Ann Intern Med 112: 485–491

    PubMed  CAS  Google Scholar 

  26. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121: 409–415

    PubMed  CAS  Google Scholar 

  27. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L (1998) Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80: 151–155

    PubMed  CAS  Google Scholar 

  28. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296–302

    Article  PubMed  CAS  Google Scholar 

  29. McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273–277

    Article  PubMed  CAS  Google Scholar 

  30. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage BH (1997) Primary pulmonary hypertension: improved longterm effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30: 343–349

    Article  PubMed  CAS  Google Scholar 

  31. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336: 111–117

    Article  PubMed  CAS  Google Scholar 

  32. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124: 820–824

    PubMed  CAS  Google Scholar 

  33. Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX (2000) Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 101: 2388–2392

    PubMed  CAS  Google Scholar 

  34. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoeper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. Ann Intern Med 132: 435–443

    PubMed  CAS  Google Scholar 

  35. Hoeper MM, Schwarze M, Ehlerding S, Adler Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866–1870

    Article  PubMed  CAS  Google Scholar 

  36. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, Lang IM (2001) Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 17: 8–13

    Article  PubMed  CAS  Google Scholar 

  37. Olschewski H, Simonneau G, Galie N, Higenbottam T, et al, for the Aerosolized Iloprost Randomized Study Group (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322–329

    Article  PubMed  CAS  Google Scholar 

  38. Simmoneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, for the Treprostinil Study Group (2002) Continuous subcutaneous infusion of Treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med 165: 800–804

    Google Scholar 

  39. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simmoneau G for the Arterial Pulmonary Hypertension and Beraprost European Trial (ALPHABET) Study Group (2002) Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind, placebo-controlled trial. J Am Coll Card 39: 1496–1502

    Article  Google Scholar 

  40. Channick RN, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson VF, Badesch DB, Roux S, Raisinio M, Bodin F, et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119–1123

    Article  PubMed  CAS  Google Scholar 

  41. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al (2002) Bosentan in patients with pulmonary artery hypertension: a randomized, placebo controlled, multicenter study. N Engl J Med 346: 896–903

    Article  PubMed  CAS  Google Scholar 

  42. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, et al (1989) Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 80: 1207–1221

    PubMed  CAS  Google Scholar 

  43. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calciumchannel blockers in primary pulmonary hypertension. Eur Respir J 12: 265–270

    Article  PubMed  CAS  Google Scholar 

  44. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81

    PubMed  CAS  Google Scholar 

  45. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580–587

    PubMed  CAS  Google Scholar 

  46. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, Stinson EB, Shumway NE (1982) Heartlung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 306: 557–564

    PubMed  CAS  Google Scholar 

  47. Tamm M, Sharples LD, Higenbottam TW, Stewart S, Wallwork J (1997) Bronchiolitis obliterans syndrome in heartlung transplantation — surveillance biopsies. Am J Respir Crit Care Med 155: 1705–1710

    PubMed  CAS  Google Scholar 

  48. Keck BM, Bennett LE, Fiol BS, Daily OP, Novick RJ, Hosenpud JD (1998) Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transplant: 39–52

  49. Meyers BF, Lynch J, Trulock EP, Guthrie TJ, Cooper JD, Patterson GA (1999) Lung transplantation: a decade of experience. Ann Surg 230: 362–370

    Article  PubMed  CAS  Google Scholar 

  50. The American Society for Transplant Physicians (ASTP)/ American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT) (1998) International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 158: 335–339

    Google Scholar 

  51. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ (1995) Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91: 2028–2035

    PubMed  CAS  Google Scholar 

  52. Rich S, Dodin E, McLaughlin VV (1997) Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 80: 369–371

    Article  PubMed  CAS  Google Scholar 

  53. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez GM, Zeballos M, et al (1998) Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32: 297–304

    Article  PubMed  CAS  Google Scholar 

  54. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339–1346

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Pulmologie, Universitätsklinik für Innere Medizin IV, Währinger Gürtel 18-20, A-1090, Wien, Österreich

    Rolf Ziesche

Authors
  1. Rolf Ziesche
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rolf Ziesche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziesche, R. Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose. Wien Klin Wochenschr 115, 351–365 (2003). https://doi.org/10.1007/BF03041488

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03041488

Key words

Search

Navigation